Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Get the latest updates from Press releases directly as they happen.
Follow now 487 followers
Last updated 2 days ago
1 day ago
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A...
12 days ago
Q4 and full year 2024 performance highlights
17 days ago
Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete...
20 days ago
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing.
20 days ago
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
20 days ago
Collaboration unites GSK and Oxford’s complementary expertise in the science of the...
21 days ago
Over 25 million people in Europe have received GSK’s shingles vaccine since...
28 days ago
Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer...
about 1 month ago
Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers
about 1 month ago
If approved, the new presentation will offer a convenient administration option to...
about 1 month ago
Regulatory designation based on promising early data in this rare bone cancer.
about 1 month ago
This is the third indication for mepolizumab in China for an IL-5...